Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteitis deformans
- Focus Adverse reactions
- Sponsors Takeda
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
- 26 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 30 Apr 2018.